Traditional pharmacological approaches such as xanthine oxidase inhibitors and uricosuric agents have shown mixed results, particularly in patients with chronic kidney disease (CKD) where treatment may not alter disease progression [3]. The gene discussed is XDH; the disease is chronic kidney disease.